Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

How did we get here? Until now, vaccines for all children under age 12 had been available under emergency use authorization (EUA) since 2022. That meant that, theoretically, all children had access to ...

The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is no ...

Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and safety of COVID-19 vaccines for young children.

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

The FDA fully approves Moderna’s Spikevax for children six months to 11 years at high risk of COVID-19. A new wave of value and momentum stocks could be setting up for major moves—and Tim ...

Business FDA approves Moderna’s new lower-dose COVID-19 vaccine FILE - The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed on Oct. 14, 2015.

The FDA approved Moderna's newest COVID vaccine, called mNEXSPIKE, for adults 65 and older, Saturday. It is also approved for those ages 12 to 64 with CDC-defined risk factors.